The Career Development Program (CDP) is an essential component of the PNW Prostate SPORE that serves to sustain and enhance our mission by attracting and nurturing new and talented research faculty. The CDP will continue to implement a strategy that has successfully developed clinical, basic, and population scientists for productive careers in translational prostate cancer research.
The specific aims are: 1. Provide research support for junior faculty, advanced fellows, and established investigators who wish to develop or refocus their careers on translational prostate cancer research;2. Provide a system for mentoring faculty and advanced fellows pursuing prostate cancer research in a broad range of disciplines;3. Create a framework in which investigators can gain exposure to, and training in, aspects of translational prostate cancer research outside their areas of expertise (e.g., a molecular biologist would be exposed to clinical issues in prostate cancer care by attending tumor boards and clinical prostate cancer conferences); 4. Attract and retain women, minorities and junior faculty who can make key contributions to translational prostate cancer research at the institutions comprising the PNW Prostate SPORE. The CDP will be coordinated between the FHCRC and the University ofWashington (UW);the Prostate Centre at the Vancouver General Hospital (VGH);and the Oregon Health Science University (OHSU). Our organizational structure works across sites and includes recruitment and monitoring of candidates by a career development committee, educational coordination through a conference and education committee, and access to more than 45 multidisciplinary investigators both within and outside the SPORE whose research interests provide relevant experience in translational prostate cancer research. The CDP educational program combines a wide spectrum of individual research opportunities, formal educational courses, and a large number of conferences and seminars in translational prostate cancer research. We plan to continue to recruit both qualified faculty members and senior research fellows who wish to expand their work in translational prostate cancer research, focusing on the inclusion of underrepresented minority applicants. In addition to SPORE grant support, this program will be augmented by substantial institutional resources.
Prostate cancer is the second most common cause of cancer deaths in men. Developing translational research scientists in prostate cancer that specialize in clinical, basic, and population sciences research will enhance our understanding of the disease biology, expand treatment options, and improve outcomes for patients.
|Kuo, Kevin F; Hunter-Merrill, Rachel; Gulati, Roman et al. (2015) Relationships between times to testosterone and prostate-specific antigen rises during the first off-treatment interval of intermittent androgen deprivation are prognostic for castration resistance in men with nonmetastatic prostate cancer. Clin Genitourin Cancer 13:6-Oct|
|True, Lawrence D (2014) Methodological requirements for valid tissue-based biomarker studies that can be used in clinical practice. Virchows Arch 464:257-63|
|Lam, Hung-Ming; Vessella, Robert L; Morrissey, Colm (2014) The role of the microenvironment-dormant prostate disseminated tumor cells in the bone marrow. Drug Discov Today Technol 11:41-7|
|Montgomery, Bruce; Cheng, Heather H; Drechsler, James et al. (2014) Glucocorticoids and prostate cancer treatment: friend or foe? Asian J Androl 16:354-8|
|Sprenger, Cynthia C T; Plymate, Stephen R (2014) The link between androgen receptor splice variants and castration-resistant prostate cancer. Horm Cancer 5:207-17|
|Tarnow, Carolin; Engels, Géraldine; Arendt, Annika et al. (2014) TMPRSS2 is a host factor that is essential for pneumotropism and pathogenicity of H7N9 influenza A virus in mice. J Virol 88:4744-51|
|O'Hurley, Gillian; Prencipe, Maria; Lundon, Dara et al. (2014) The analysis of serum response factor expression in bone and soft tissue prostate cancer metastases. Prostate 74:306-13|
|Barnett, Christine M; Heinrich, Michael C; Lim, Jeong et al. (2014) Genetic profiling to determine risk of relapse-free survival in high-risk localized prostate cancer. Clin Cancer Res 20:1306-12|
|Mostaghel, Elahe A; Plymate, Stephen R; Montgomery, Bruce (2014) Molecular pathways: targeting resistance in the androgen receptor for therapeutic benefit. Clin Cancer Res 20:791-8|
|Chéry, Lisly; Lam, Hung-Ming; Coleman, Ilsa et al. (2014) Characterization of single disseminated prostate cancer cells reveals tumor cell heterogeneity and identifies dormancy associated pathways. Oncotarget 5:9939-51|
Showing the most recent 10 out of 227 publications